Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806)
|
|
- Terence May
- 6 years ago
- Views:
Transcription
1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806) Presented by: Cap Uldriks, FDA Daniel P. Olivier, CCS Page 1
2 Objectives Define regulatory reporting rules based on on established standards Simplify regulatory reporting decision making Establish defensible basis to to support compliance with with reporting regulations Reduce risk risk of of non-compliance observations Page 2
3 AGENDA Reporting Regulations Evaluating Safety Risks Defining the Strategy Summary Page 3
4 Reporting + Regulations Page 4
5 21 21 CFR Part 803: Medical Device Reporting MDR reportable event means: (1) User facilities become aware of information that reasonably suggests a device has or may have caused or contributed to a death or serious injury; or (2) Manufacturers or importers become aware of information that reasonably suggests one of their marketed devices: (i) May have caused or contributed to a death or serious injury, or (ii) Has malfunctioned and that the device or a similar device marketed by the manufacturer or importer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur. Page 5
6 Compliance Program Guidance for CFR Part 803: Medical Device Reporting If the event is likely to cause or contribute to death or serious injury" then the event is reportable The preamble offers the following guidance, i.e., a malfunction report is required when: 1.The chance of a death or serious injury occurring as a result of the recurrence of the malfunction is not remote 2.The consequences of the malfunction affect the device in a catastrophic manner that may lead to a death or serious injury (Class I Recall) Page 6
7 21 21 CFR Part 806: Corrections and Removal Reporting Sec Reports of corrections and removals. (a) Each device manufacturer or importer shall submit a written report to FDA of any correction or removal of a device initiated by them: (1) To reduce a risk to health posed by the device; or (2) To remedy a violation of the act caused by the device which may present a risk to health unless the information has already been provided under Part 803 or Part 1004 or the action is exempt from the reporting under 806.1(b). Page 7
8 Compliance Program Guidance for CFR Part 806: FDA Corrections and Removals Reporting Risk to Health - The key concept to determine whether an event is reportable under Part 806: Use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or an outcome where the probability of serious adverse health consequences is remote (Class II Recall). Page 8
9 21 21 CFR Part 7.3: Recall Class Definitions Class I is a situation in which there is reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death (criteria for 803 reporting) Class II is a situation in which there is reasonable probability that the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote (criteria for 806 reporting) Class III is a situation in which there is reasonable probability that the use of, or exposure to, a violative product is not likely to cause serious adverse health consequences Page 9
10 Evaluating + Safety Risk Page 10
11 Risk Evaluation, Severity Severity* - Assess the worst possible consequence, defined by degree of injury or illness that could occur. Severity classification identified as follows: Major, may cause death or serious injury Moderate, may cause non-serious injury Minor, not expected to cause injury *Based on Levels of Concern defined in Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, Food and Drug Administration, May 11,2005. Page 11
12 MIL-STD 882D* Severity Levels Severity: Suggested mishap categories: Catastrophic, could result in death, permanent total disability, loss exceeding $1M Critical, could result in permanent partial disability, or that may result in hospitalization of at least three people, $200k-$1M loss Marginal, could result in injury resulting in more than one lost work day, $10K-$200K loss Negligible, could result in injury resulting in less than one lost day, less than $10K * Standard Practice for System Safety, MIL-STD-882D, Department of Defense, February 10, 2000, Appendix A, Table A-1, page 18 Page 12
13 ISO 14971:2000* Severity Levels Severity: levels may be descriptive, e.g. Catastrophic Serious Critical Marginal Negligible * Medical device - Application of safety risk management to medical devices, ANSI/AAMI/ISO 14971:2000 section E.2.2, page 32 Page 13
14 Consolidated Severity Levels MIL-STD 882D ISO 14971:2000 FDA Guidance Catastrophic Catastrophic Major Serious Major Critical Critical Major Marginal Marginal Moderate Negligible Negligible Minor Page 14
15 MIL-STD-882D* Risk Evaluation, Probability Probability* - Probability that a mishap will occur during the planned life expectancy of the system: Frequent - Likely to occur often (X > 10-1 ) Probable - Will occur several times in the life of the system. (10-1 >X >10-2 ) Occasional - Likely to occur sometime in the life of the system. (10-2 >X >10-3 ) Remote - Unlikely but possible to occur in the life of the system. (10-3 >X >10-6 ) Improbable - So unlikely, it can be assumed occurrence may not be experienced (X < 10-6 ) * Standard Practice for System Safety, MIL-STD-882D, Department of Defense, February 10, 2000, Appendix A, Table A-2, page 19 Page 15
16 ISO 14971:2000* Risk Evaluation, Probability Probability - Probability estimation examines the initiating events or circumstances and the sequences of events that are of concern: Frequent Probable Occasional Remote Improbable Incredible * Medical device - Application of safety risk management to medical devices, ANSI/AAMI/ISO 14971:2000 section E.2.1, page 31 Page 16
17 Proposed Risk Assessment Matrix for FDA Adverse Event Reporting Frequent Probable Occasional Remote Improbable Minor Moderate Major Note: Probability level of Incredible from ISO 14971:2003 not included Page 17
18 Defining the Strategy Page 18
19 Compliance Program Guidance for CFR Part 803: Medical Device Reporting If the event is likely to cause or contribute to death or serious injury" then the event is reportable The preamble offers the following guidance, i.e., a malfunction report is required when: 1.The chance of a death or serious injury occurring as a result of the recurrence of the malfunction is not remote; 2.The consequences of the malfunction affect the device in a catastrophic manner that may lead to a death or serious injury Page 19
20 Proposed Risk Assessment Matrix for FDA Adverse Event Reporting Frequent Probable Occasional Remote Improbable Minor Moderate Major MDR MDR MDR Note: Probability level of Incredible from ISO 14971:2003 not included Page 20
21 Compliance Program Guidance for CFR Part 806: FDA Corrections and Removals Reporting Reports are NOT required IF: The information has already been reported to FDA under the MDR regulation, 21 CFR Part 803 or under 21 CFR 1004 (Replacement of Electronic Products). The key concept for determining when an event is reportable is the CAR regulation's definition of risk to health: Use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or an outcome where the probability of serious adverse health consequences is remote (Class II Recall). Page 21
22 Proposed Risk Assessment Matrix for FDA Adverse Event Reporting Frequent Minor Moderate NR CAR Major MDR Probable NR CAR MDR Occasional NR CAR MDR Remote NR NR CAR Improbable NR NR NR NR - Not reportable CAR - Reportable under 21 CFR Part 806 MDR - reportable under 21 CFR Part 803 Page 22
23 Summary Page 23
24 Defining Reporting Strategy Reference to external standards/guidelines provides defensibility for decision making Established rules provide: consistency use of common terminology facilitate training Established rules reduce compliance risk Page 24
25 References Medical device - Application of safety risk management to medical devices, ANSI/AAMI/ISO 14971:2000. Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, FDA, Office of Device Evaluation, May 11, Standard Practice for System Safety, MIL-STD-882D, Department of Defense, February 10, CFR Part 7 Enforcement Policy, US Federal Register, Food and Drug Administration. Page 25
AFDO Conference June 9, Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide
AFDO Conference June 9, 2009 Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide Government Agencies 483 observations A violation of the FD&C Act involving
More informationFDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions
FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions 23 January 2017 On December 27, 2016, the U.S. Food and Drug
More informationBEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE. Yuan Xu 18- JAN- 2018
BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE Yuan Xu 18- JAN- 2018 Background AGENDA What is Medical Device? What is 510(k)? Principles of best practices of device
More informationUsing Recall Data to Assess the 510(k) Process
Using Recall Data to Assess the 510(k) Process Ralph F. Hall Distinguished Professor and Practitioner University of Minnesota Law School July 28, 2010 Acknowledgments 2 Disclosures 3 Agenda I. Research
More information2/17/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota
Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ FDA Authority Medical Device Act of 1976 FDA Modernization Act of 1997 Federal Food, Drug and Cosmetic Act (FFDCA)
More informationProf. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota
Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ FDA Authority Medical Device Act of 1976 FDA Modernization Act of 1997 Federal Food, Drug and Cosmetic Act (FFDCA)
More informationPreparing a US FDA Medical Device 510(K) Submission
Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via
More informationTOBACCO PRODUCT OR MEDICAL PRODUCT?
TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:
More informationMedidée Services SA. Nano-Tera.ch. 05 February 2015 part 4. Intro ISO GMP - GLP Pierre-Alain Sommer
Nano-Tera.ch 05 February 2015 part 4 Intro ISO GMP - GLP Pierre-Alain Sommer Pierre-alain.sommer@medidee.com www.medidee.com Nano-Tera 2015 05.02.2015 Introduction to ISO 13485, cgmp s and GLP s Context
More informationResidual Solvents: FDA/ Regulatory Perspective
Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements
More informationSeptember 28, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
September 28, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. : Center for Devices and Radiological Health 510(k)
More information510(k) submissions. Getting US FDA clearance for your device: Improving
Getting US FDA clearance for your device: Improving 510(k) submissions Audrey Swearingen, RAC Director, Regulatory Affairs Telephone: +1 512.222.0263 Email: aswearingen@emergogroup.com Download this white
More informationEffective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products
Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Quick Facts Retailers that mix and prepare e-liquids or create or modify vaporizers
More informationDETERMINING WHETHER AN ACTIVITY IS HUMAN SUBJECTS RESEARCH AS DEFINED BY FEDERAL REGULATIONS
Page 1 of 6 Human Research Protection Page: 1 of 6 DETERMINING WHETHER AN ACTIVITY IS HUMAN SUBJECTS RESEARCH AS DEFINED BY FEDERAL REGULATIONS DESCRIPTION Any proposed activity involving contact with
More informationDraft Guidance for Industry and FDA Staff
Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document
More informationOverview of the Legal Framework for Medical Device Regulation in the United States
1 Overview of the Legal Framework for Medical Device Regulation in the United States Ellen J. Flannery This chapter provides an overview of the legal framework for medical device regulation in the United
More informationRaritan Pharmaceuticals, Inc. 6/20/17
Raritan Pharmaceuticals, Inc. 6/20/17 U.S. Food & Drug Administration Division of Pharmaceutical Quality Operations I New Jersey District 10 Waterview Boulevard, 3rd Floor Parsippany, NJ 07054 June 20,
More informationUNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products
UNITED STATES REGULATION OF TOBACCO PRODUCTS Presented by Mitch Zeller Center Director FDA Center for Tobacco Products May 24, 2016 OVERVIEW OF TODAY S PRESENTATION Highlights of the Deeming Final Rule
More informationMedication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski
Medication errors Impact of medication error guidance and regulation on drug-device combination products June 2017 Dan Wozinski Agenda Understand the management of medication errors within global requirements
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry Bar Code Label Requirements Questions and Answers (Question 12 Update) DRAFT GUIDANCE This guidance document is for comment purposes only. Submit comments
More information(Cochineal Extract and Carmine: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain These Color Additives)
ก ก 2553 ก : ก (Cochineal Extract and Carmine: Declaration by Name on the Label of All Foods and Cosmetic Products That Contain These Color Additives) : ก ก ก : ก ก ก : 2552 : 2552 1 ก 5 ก : ก (Cochineal
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 01/28/2016 and available online at http://federalregister.gov/a/2016-01690, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationFDA 510(k) 101 The Basics
FDA 510(k) 101 The Basics Floyd G. Larson President, PaxMed International San Diego, CA OMTEC June 17, 2010 Chicago Agenda History of 510(k) process FDA s risk based approach FDA guidance and standards
More informationUPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)
UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) Mitch Zeller, J.D. Director, FDA May 4, 2017 CENTER FOR TOBACCO PRODUCTS AGENDA Update on Regulations and Guidances: Deeming Update on Science Update
More informationPublic Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA Telephone: 510/
Department of Health and Human Services Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Telephone: 510/337-6700 WARNING LETTER December
More informationPremarket Notification: Analysis of FDA Recall Data
Premarket Notification: Analysis of FDA Recall Data Director, Medical Device Safety Institute Beth Israel Deaconess Medical Center Boston, MA IOM 510(k) Workshop July 28, 2010 Disclosure FDA Consultant
More informationManual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010
Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 January 2010 Version 2.0 Table of Contents 1. INTRODUCTION...1 1.1 Scope... 1 1.2 Purpose... 1 1.3 Responsibilities...
More information2014 FDA/JIFSAN Food & Nutrition Webinar
2014 FDA/JIFSAN Food & Nutrition Webinar Medical Foods Shawne Suggs-Anderson, MMSc, _ RD Infant Formula and Medical Foods Staff ONLDS/CFSAN/FDA September 23, 2014 53 Main Objectives History What is a Medical
More informationAgency Information Collection Activities; Submission for Office of Management and
This document is scheduled to be published in the Federal Register on 03/04/2019 and available online at https://federalregister.gov/d/2019-03824, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationAgency Information Collection Activities; Submission for Office of Management and
This document is scheduled to be published in the Federal Register on 02/19/2019 and available online at https://federalregister.gov/d/2019-02596, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationUse of Standards in Substantial Equivalence Determinations
Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration
More informationHieber's Pharmacy 12/5/17
Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED
More informationLIVE INTERACTIVE YOUR DESKTOP. Food Recall Process. Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement
LIVE INTERACTIVE LEARNING @ YOUR DESKTOP Food Recall Process Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement Wednesday, December 9, 2009 LEGAL ISSUES Code of Federal Regulations
More informationGeneral Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff
General Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff Document issued on: July 29, 2016. The draft of this document was issued on January 20, 2015.
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f J Dallas District 4040 North Central Expressway Dallas, Texas 75204-3145 Ref: 2004-DAL-WL-03 WARNING LETTER CERTIFIED MAIL RETURN
More informationRECALL / EVENT INVESTIGATION & PATIENT LOOK BACK
RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK Federal, State and AABB requirements for nonconforming product investigation and recipient look back for adverse impact Stacy Ralston MPH, CLS (ASCP), RAC
More informationNRMP Reporting Requirements
NRMP ing s (s will be made to NAVENVIRHLTHCEN Medical (1) (i) The total dose delivered differs from the prescribed dose by 20 percent or more; (ii) The total dosage delivered differs from the prescribed
More informationFinal Rules Preventive Controls for Human Food Preventive Controls for Animal Food
Final Rules Preventive Controls for Human Food Preventive Controls for Animal Food http://www.fda.gov/fsma THE FUTURE IS NOW 1 Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive
More information40 CFR PART DENTAL OFFICE POINT SOURCE CATEGORY
40 CFR PART 441 - DENTAL OFFICE POINT SOURCE CATEGORY 441.10 Applicability. (a) Except as provided in paragraphs (c), (d), and (e) of this section, this part applies to dental dischargers. (b) Unless otherwise
More informationTown and Country Compounding and Consultation Services, LLC 10/17/17
Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 9 Inspections, Compliance, Enforcement, and Criminal Investigations Phoenix Medical Devices, LLC 9/29/2009 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationSAMED Position: Reuse of SUDs
SAMED Position: Reuse of SUDs What We Will Cover SAMED - who we are and what we do Definition of single-use device Overview of single-use device reprocessing Overview of SA and other countries regulatory
More informationIn Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review
In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review Cardiac Safety Research Consortium December 3, 2015 Lea Carrington Division of Immunology and Hematology Devices Office of In
More informationStandards of Conduct for Transmission Providers
Standards of Conduct for Transmission Providers Posted and Effective as of December 30, 2016 Puget Sound Energy ( PSE ) is a public utility that owns, operates, and controls facilities used for the transmission
More informationCompliance with the Dental Rule in Virginia
Compliance with the Dental Rule in Virginia Industrial Waste and Pretreatment Conference Charlottesville, VA March 6 th, 2018 Deborah DeBiasi, DEQ Deborah.DeBiasi@deq.Virginia.gov 804-698-4028 Purpose
More informationBorder Issues and Statistics: Regulatory Activities. Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas
Border Issues and Statistics: Regulatory Activities Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas U.S. Food & Drug Administration Mission Statement The Food & Drug Administration
More informationChildren s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Research That Must Be Reviewed by the IRB
Page: 1 of 5 I. PURPOSE II. III. IV. To provide guidance on the types of research activities that are subject to review and approval by the Committees for the Protection of Human, which comprise the Institutional
More informationAlignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference
Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference Donald Kautter US Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food
More informationFDA Basics FDA s Import Operations: How FDA Regulates Imported Products
FDA Basics FDA s Import Operations: How FDA Regulates Imported Products Carlos W. Hernandez Compliance Officer U.S. Food and Drug Administration Global Regulatory Operations and Policy Office of Regulatory
More informationStonegate Pharmacy LP 11/10/16
Stonegate Pharmacy LP 11/10/16 November 10, 2016 2017 DAL WL 03 WARNING LETTER UPS Overnight Rene F. Garza, Pharm.D., Chief Executive Officer Stonegate Pharmacy, LP 2501 W. William Cannon Drive, Suite
More informationThe Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))
The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) January 12, 2011 Cristi Stark, MS Senior Regulatory Health Project Manager Office
More informationU.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health. Preface
U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Preface Public Comment: The Food and Drug Administration (FDA) is announcing the availability
More informationKey CDRH Regulatory Initiatives
Key CDRH Regulatory Initiatives Revamping the Submission Process Creating New Strategies Ralph F. Hall University of Minnesota Law School Counsel Faegre Baker & Daniels May 8, 2012 Purpose of Today s Program
More informationMedical Device Approval and Product Recalls
Medical Device Approval and Product Recalls Presented by Sean P. Farley, MBA, CMRP Director, Organizational Procurement Virginia Mason Medical Center President, WSHMMA - Introduction and the Business Environment
More informationOn December 27, 2017, the Lieutenant Governor signed into law several new requirements
OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following
More informationFamily Smoking Prevention and Tobacco Control Act. Comments regarding crop protection agents
Family Smoking Prevention and Tobacco Control Act (PUBLIC LAW 111-31 JUNE 22, 2009) Comments regarding crop protection agents Presentation Objectives What is the intent of FDA in regulating CPAs? What
More informationSFIREG Issue Paper: Pesticide Use on Cannabis State Established Pesticide Residue Action Levels
SFIREG Issue Paper: Pesticide Use on Cannabis State Established Pesticide Residue Action Levels Introduction to Issue: In recent years, with the approval of medical and recreational use of marijuana in
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationContiTech North America
ContiTech North America Dear Customer: Certain products now contain the following warning language about certain chemicals or compounds that may be found in Continental ContiTech s products or component
More informationQA Regulatory forum: Classification and Risk assessment according to MDR Date : T h e r e s e. A l b i n s s o m e d q t e c h.
QA Regulatory forum: Classification and Risk assessment according to MDR Date : 05.04.2018 THERESE ALBINSSON T h e r e s e. A l b i n s s o n @ m e d q t e c h. s e MedQtech AB MedQtech AB is a consultant
More information4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch
Libia Lugo Drug Specialist San Juan District Office Investigations Branch The Food and Drug Administration (FDA) responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico,
More information510(k) 21 Summary of Safety and Effectiveness
510(k) 21 Summary of Safety and Effectiveness This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirement of 21 CFR 807.92. Submitter's Identification:
More informationGuidance for the Network Review of Chemotherapy Errors
Guidance for the Network Review of Chemotherapy Errors For approvals and version control see Document Management Record on page 8 Doc Ref: AngCN-CCG-C31 Approved and published: March 2013 Page 1 of 8 Table
More informationMIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE
ISSUED BY: Research PAGE: 1 of 6 REPLACES POLICY DATED: EFFECTIVE DATE: 08/09/2012 DISTRIBUTION: Departmentwide APPROVED BY: Andrews, April (SVP/CECO), BOD Audit and Compliance Committee, Perdomo, Jose
More informationPIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 040-1 3 Appendices 1 January 2019 PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES PIC/S January 2019 Reproduction
More informationJuly 10, X-spine Systems, Incorporated David Kirschman, MD Chief Medical Officer 452 Alexandersville Road Miamisburg, Ohio 45342
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service July 10, 2015 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 X-spine
More informationATTACHMENT A AdvaMed Comments Draft-Guidance for Industry and FDA Staff -510(k) Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device Line(s) No. Line or lines numbers of the
More informationInformational Memo. Communication Assistance Compliance Standards for Individuals who are Deaf. ODP Communication Number: Memo
Informational Memo Communication Assistance Compliance Standards for Individuals who are Deaf ODP Communication Number: Memo 018-15 The mission of the Office of Developmental Programs is to support Pennsylvanians
More informationCOMMON RULE 2019 IMPLEMENTATION DATE: JANUARY 21, 2019
COMMON RULE 2019 IMPLEMENTATION DATE: JANUARY 21, 2019 HISTORY The Common Rule has been in effect since 1991, and was adopted by 15 federal departments and agencies, including the Department of Health
More informationShawn Stevens Food Industry Consultant and Lawyer
Shawn Stevens Food Industry Consultant and Lawyer stevens@foodindustrycounsel.com 920.698.2561 COMPLYING WITH FSMA S PREVENTIVE CONTROL RULE AS A SMALL BUSINESS COMPLYING WITH FSMA S PREVENTIVE CONTROL
More informationClass II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA
Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Document issued on: November 12, 2002 This document supersedes the
More informationChecklist of issues to be considered by food business operators when implementing Commission Regulation (EC) No 2073/2005
Checklist of issues to be considered by food business operators when implementing Commission Regulation 1. General requirements 2. Sampling foodstuffs and testing against the relevant criteria 2.1 Validation
More informationDEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J
JON S. CORZINE Governor DEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J. 08625-0360 www.nj.gov/health HEATHER HOWARD Commissioner TO: FROM: Public Health Council Heather Howard Commissioner
More informationGOOD REGULATORY REVIEW PRACTICES WORKING GROUP UPDATE. Working Group Chair: Melissa Torres US Food and Drug Administration
GOOD REGULATORY REVIEW PRACTICES WORKING GROUP UPDATE Working Group Chair: Melissa Torres US Food and Drug Administration GOALS The Good Regulatory Review Practices working group has focused efforts on
More informationFood Additives Program
U.S. FDA s Food Additive Program: An Update on Resources and Challenges 18 th Food Packaging Law Seminar October 11, 2017 Arlington, VA 1 Food Additives Program Dennis Keefe, PhD Director, Office of Food
More informationResponsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA.
Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA (Laser Notice 51) Document issued on: May 27, 2001 U.S. Department of Health
More informationPrimer: Medical Device User Fee Amendments Han Zhong l September 2011
Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Introduction The Medical Device User Fee and Modernization Act (MDUFMA or MDUFA) is a set of agreements between the Food and Drug Administration
More informationInter-Agency Overlap and Jurisdictional Boundaries
Inter-Agency Overlap and Jurisdictional Boundaries FDLI Food Advertising, Labeling, and Litigation Conference September 14, 2017 Jessica P. O Connell Covington & Burling LLP jpoconnell@cov.com 1 FDA Approach/Perspective
More informationTHE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE
THE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE An overview by Sarah Vugigi, M. Pharm, Elys Chemical Industries Ltd, Nairobi, Kenya INTRODUCTION This guidance describes
More informationCDRH: 510(k)S AND SCIENCE IN REGULATOR DECISION-MAKING. lannery, Scott Danzis and Christopher Pruitt. November 2010 SPECIAL REPRINT
November 2010 SPECIAL REPRINT CDRH: 510(k)S AND SCIENCE IN REGULATOR ORY DECISION-MAKING By Ellen Flanner lannery, Scott Danzis and Christopher Pruitt Reproduced with the kind permission of Global Regulatory
More informationFDA Regulation of Diagnostic Tests Jeffrey N. Gibbs Hyman, Phelps & McNamara, P.C. Washington, DC
AIPLA Annual Meeting Joint Biotechnology Committee/ Special Committee on FDA Law Program October 21, 2010 Marriott Wardman Park Hotel Washington, DC FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs
More informationEyewash and Safety Showers HM 20 Page 1
Policy Subject: Safety Showers and Eyewash Effective: 12/01/09 Stations Affected Area/Department: University of Tennessee Reviewed/Revised: 12/15/08 Policy It shall be the policy of the University of Tennessee
More informationIAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005
IAASB Main Agenda (March 2005) Page 2005 579 Agenda Item 13-F DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 Introduction This memorandum provides some background to, and
More informationPROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS. LCB File No. R July 6, 2001
PROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS LCB File No. R062-01 July 6, 2001 EXPLANATION Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY:
More informationCITY OF PALMER, ALASKA. Ordinance No
Initiative Petition Submitted to City Clerk: July 3, 2012 Petition Certified by City Clerk: July 6, 2012 Measure Placed Before the Voters at the Regular Election of: October 2, 2012 Proposition No. 3,
More informationCERTIFICATE OF ANALYSIS. tel: fax:
CERTIFICATE OF ANALYSIS 300 Technology Drive Christiansburg, VA 24073. USA inorganicventures.com tel: 800.669.6799. 540.585.3030 fax: 540.585.3012 info@inorganicventures.com 1.0 ACCREDITATION / REGISTRATION
More informationDear Valued Customer,
Dear Valued Customer, As part of our mission to return clean water to our environment, the Washington Suburban Sanitary Commission's (WSSC) Industrial Discharge Control Program is responsible for monitoring
More informationIMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE 2010/32/EU ON PHARMACY ASEPTIC PRACTICES IN THE UK
IMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE 2010/32/EU ON PHARMACY ASEPTIC PRACTICES IN THE UK Dr Alison Beaney Regional QA Specialist NE and N Cumbira IMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE
More informationTGA: the current regulatory reform agenda
TGA: the current regulatory reform agenda ASMI 2012 Conference: 13 November 2012 Future proofing the consumer healthcare industry Dr John Skerritt, National Manager The Therapeutic Goods Administration
More informationCurrent Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food
Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Lillian Hsu, Ph. D. 2018 American Hop Convention January 25, 2018 2 Who is Covered by Part 117? In
More informationGuidance - IDE Early/Expanded Access for Devices
Guidance - IDE Early/Expanded Access for Devices An unapproved medical device may normally only be used on human subjects through an approved clinical study in which the subjects meet certain criteria
More informationThe Basics of the U.S. FDA s Regulation of Materials Used in Food Packaging Applications
The Basics of the U.S. FDA s Regulation of Materials Used in Food Packaging Applications RadTech UV & EB Technology Expo & Conference 2012 Presented by David J. Ettinger Partner Keller and Heckman LLP
More informationAl Garcia. CIPCA October 12, 2018
Al Garcia CIPCA October 12, 2018 Final 2016 Effluent Limitation Guidelines Plan Published for Public Comment May 2, 2018 https://www.gpo.gov/fdsys/pkg/fr- 2018-05-02/pdf/2018-09320.pdf Final 2016 ELG Plan
More informationRegulatory Update: Food Safety and Nutrition
Regulatory Update: Food Safety and Nutrition Ricardo Carvajal Hyman, Phelps & McNamara, P.C. www.hpm.com www.fdalawblog.net North American Millers Association March 2015 Today s Agenda FSMA Update Biological
More informationListing of Color Additives Exempt from Certification; Synthetic Iron Oxide
This document is scheduled to be published in the Federal Register on 03/20/2015 and available online at http://federalregister.gov/a/2015-06418, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationMulti Analyte Custom Grade Solution
1.0 ACCREDITATION / REGISTRATION INORGANIC VENTURES is accredited to ISO Guide 34, "General Requirements for the Competence of Reference Material Producers" and ISO/IEC 17025, "General Requirements for
More informationDental Amalgam Rule Update
Dental Amalgam Rule Update Pacific Northwest Pretreatment Workshop Vancouver, Washington September 11, 2017 Jay Pimpare EPA New England Regional Pretreatment Coordinator 1 40 CFR 441 Dental Rule Schedule
More informationTalon Compounding Pharmacy 10/3/17
Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING
More informationDonald W. Guthner Orgenix, LLC Ill Hill Road. Douglassville, PA (888) ORGENIX ( ) (484) (FAX) Intramedullary Nails, Nails
K070741 ~, SANATMETAL Manufacturer of Orthopaedic and Traumatologic Products H-3301, Eger Faiskola ut 5. Phone: +(36)36-512-900 Fax: +(36)36-512-932 e-mail: metalasanatmetal.hu 510(k) Statement of Summary
More information